Intermediate-dose cytosine arabinoside in the treatment of recurrent or refractory non-Hodgkin's lymphoma.
Twelve patients with recurrent or refractory non-Hodgkin's lymphoma (NHL) were treated with an intermediate-dose of cytosine arabinoside (CA) by continuous i.v. infusion in combination with daunorubicin (DNR). Of the 10 patients evaluated, one obtained a complete response (CR) and three partial responses (PR), and an almost complete disappearance of the tumor for three weeks (minor response) was seen in two patients. Severe myelosuppression was a dose-limiting factor. Intermediate-dose CA is effective for recurrent or refractory NHL but it needs to be combined with the proper partner drugs to obtain better therapeutic results.